Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
DOI: https://doi.org/10.2147/dddt.s451223
IF: 4.3188
2024-06-07
Drug Design Development and Therapy
Abstract:Serena Maria Boccia, 1, &ast Carolina Maria Sassu, 1, &ast Raffaella Ergasti, 1 Laura Vertechy, 1 Adriana Ionelia Apostol, 2 Eleonora Palluzzi, 1 Anna Fagotti, 1, 2 Giovanni Scambia, 1, 2 Claudia Marchetti 1, 2 1 Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, 00136, Italy; 2 Dipartimento Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, 00136, Italy &astThese authors contributed equally to this work Correspondence: Claudia Marchetti, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, 00136, Italy, Email In the era of single and combination maintenance therapies as well as platinum and Poly (ADP-ribose) polymerase inhibitors (PARPi) resistance, the choice of subsequent treatments following first-line platinum-based chemotherapy in recurrent ovarian cancer (ROC) patients has become increasingly complex. Within the ovarian cancer treatment algorithm, particularly in the emerging context of PARPi resistance, the role of trabectedin, in combination with pegylated liposomal doxorubicin (PLD) still preserves its significance. This paper offers valuable insights into the multifaceted role and mechanism of action of trabectedin in ROC. The main results of clinical trials and studies involving trabectedin/PLD, along with hints of Breast Cancer genes (BRCA)-mutated and BRCAness phenotype cases, are critically discussed. Moreover, this review provides and contextualizes potential scenarios of administering trabectedin in combination with PLD in ROC, according to established guidelines and beyond. Keywords: ovarian cancer, trabectedin, platinum eligibility Ovarian cancer is frequently diagnosed at advanced stages, and it often recurs despite an optimal initial treatment, which includes complete cytoreductive surgery and chemotherapy with platinum compounds followed by maintenance with Poly (ADP-ribose) polymerase inhibitors (PARPi) or bevacizumab. 1–6 Recurrent ovarian cancer (ROC) is still a major challenge in the landscape of gynecologic oncology. 7–9 Indeed, ROC usually presents as a complex clinical scenario that requires a multidisciplinary approach. 10 Moreover, several key concepts need to be addressed before deciding treatment at recurrence, such as the timing from prior platinum therapy, the tumor's histology, the BReast CAncer (BRCA) mutational status, previous maintenance therapies, and side effects related to previous treatments. Among the possible choices in the ROC setting, the association of trabectedin plus pegylated liposomal doxorubicin (PLD) is still the only non-platinum doublet approved to treat platinum-sensitive ROC, defined classically as disease recurrence after 6 months of platinum-based chemotherapy. 11 This approval comes from the results of the OVA-301, 12 a randomized clinical trial that showed the superiority of trabectedin plus PLD over PLD alone in ROC patients, particularly in those recurring after 6–12 months from the last platinum cycle. Subsequently, other randomized and observational studies have investigated the role of trabectedin in ROC, with discordant results. Nowadays, the classical definition of platinum sensitivity has been revised and includes the concept of "platinum eligibility": if there is a reasonable likelihood that patients might respond to platinum rechallenge— in case of absence of progression during platinum-based therapy or shortly thereafter and no contraindications to platinum— the patients may be considered as "platinum eligible" and therefore might receive platinum-based chemotherapy. 13,14 However, in the current manuscript, we will use the classical definition of platinum sensitivity, given that several clinical trials were conducted using this earlier definition. By a question-based approach, this work is dedicated to unraveling the role of trabectedin in treating ROC, analyzing both the pros and cons that have emerged in the various studies. Moreover, our aim is also to explore the role of trabectedin in the current times, in which PARPi-induced platinum resistance has emerged as a critical challenge in ovarian cancer treatment. Trabectedin manifests its multifaceted mechanism of action through two principal routes. Firstly, it exercises a targeted influence on DeoxyriboNucleic Acid (DNA) within malignant cells, causing cell cycle arrest and inducing apoptosis. 15 Secondly, trabectedin displays a distinct mechanism of action related to its impact on the tumor microenvironm -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal